Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Tenofovir (Viread®) Access for Poor Countries

December 20, 2002

On December 17 Gilead Sciences announced that it would make its antiretroviral (tenofovir disoproxil fumarate, brand name Viread) available at cost to qualified organizations providing HIV treatment in all 53 nations in Africa, and 15 additional countries classified as "least developed" by the United Nations. The company said the program would be running by the second quarter of 2003. Information and technical assistance in applying for and using the drug will also be provided.

Also, Gilead will participate in the 3,000-patient Development of Antiretroviral Therapies (DART) study, sponsored by the UK's Medical Research Council, which will begin in 2003 in Uganda and Zimbabwe, to evaluate antiretroviral treatment strategies where resources are limited. In addition it is studying tenofovir to prevent transmission of HIV.

The text of the press announcement is at: www.gilead.com/wt/sec/pr_1040081128. For more information about the drug, see www.viread.com.


Comment

Tenofovir is an important drug because it is easy to use (one pill per day), has less problem with side effects than most antiretrovirals, and leads to relatively slow development of HIV drug resistance. However, side effects and drug resistance do occur -- and resistant virus is likely to be cross-resistant to AZT and to some other HIV drugs as well. So when used to treat existing HIV infection, tenofovir must be combined with other antiretrovirals to reduce this resistance.

Advertisement
This is not the only program to provide an antiretroviral at cost in some poor countries. It may be better designed than some of the others, in reducing cumbersome country-by-country negotiation and administration.

There are some concerns. "At cost" can translate to several times the price at which a generic manufacturer could sell the same drug at a profit. This is because proprietary pharmaceutical companies have so high a profit margin on each pill sold that they have little incentive to automate production efficiently. Also, accounting practices can differ greatly, including which expenses to count in the "cost" of a particular operation. The real issue is not to get rid of profit, but to develop workable systems for getting treatment to people who cannot afford rich-country market prices, using both efficient production and public funding. If companies could profit by doing this right, everyone would be better off.

It is impossible to solve all problems at once. Gilead did not have to do anything, and we welcome its program as a step in the right direction.


ISSN # 1052-4207

Copyright 2002 by John S. James. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used.



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by AIDS Treatment News. It is a part of the publication AIDS Treatment News.
 
See Also
More on Generic/Discount HIV Drug Access in the Developing World

Tools
 

Advertisement